Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Vidutolimod · CMP001

Vaccine (Recombinant protein vaccine) · Immune activation, directed at Toll-like receptor 9 (TLR9) · developed by Regeneron Pharmaceuticals

Phase 2 Most advanced trial
REGN Developer

What is Vidutolimod?

Vidutolimod is a virus-like particle built from the Qbeta bacteriophage capsid that encapsulates a CpG-A oligodeoxynucleotide TLR9 agonist. The particles are taken up by antigen-presenting cells, where the oligonucleotide releases and activates intracellular TLR9 to stimulate innate immune signaling. It is studied in locally advanced basal cell carcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
CMP001
Drug type
Vaccine (Recombinant protein vaccine)
Targets
Toll-like receptor 9 (TLR9)
Mechanism
Immune activation, directed at Toll-like receptor 9 (TLR9)
Pathways
innate immune signaling
Therapy area
Oncology
Developer
Regeneron Pharmaceuticals (REGN)
Also in trials of
PFE
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
D68OW5RS98

Conditions studied

Locally Advanced Basal Cell Carcinoma

Other drugs acting on TLR9

More from Regeneron Pharmaceuticals

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the REGN page.

Follow REGN, the company behind Vidutolimod

See REGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

REGN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.